CEACAM5 and familial pancreatic carcinoma: Conversely, treatment with MK-2206, BYL-719, BRD-K85133207, semagacestat, PDMP, vorapaxar, linsitinib and PF-543 had a better impact on the pancreatic cancer cell lines with lower levels of CEACAM5 (Fig. 5I-P), which means that those inhibitors could be used for clearance of CEACAM5low/− pancreatic cancer cells.